WO2001051051A3 - Agents, such as nicotinamide or cadpr for the treatment of skin disorders - Google Patents

Agents, such as nicotinamide or cadpr for the treatment of skin disorders Download PDF

Info

Publication number
WO2001051051A3
WO2001051051A3 PCT/IL2001/000017 IL0100017W WO0151051A3 WO 2001051051 A3 WO2001051051 A3 WO 2001051051A3 IL 0100017 W IL0100017 W IL 0100017W WO 0151051 A3 WO0151051 A3 WO 0151051A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
cadpr
nicotinamide
agents
skin disorders
Prior art date
Application number
PCT/IL2001/000017
Other languages
French (fr)
Other versions
WO2001051051B1 (en
WO2001051051A2 (en
Inventor
Avikam Harel
Olga Bloch
Original Assignee
Avikam Harel
Olga Bloch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE60121303T priority Critical patent/DE60121303T2/en
Priority to AU23929/01A priority patent/AU782558B2/en
Priority to EP01900231A priority patent/EP1259240B8/en
Priority to IL15070601A priority patent/IL150706A0/en
Priority to CA2396186A priority patent/CA2396186C/en
Application filed by Avikam Harel, Olga Bloch filed Critical Avikam Harel
Publication of WO2001051051A2 publication Critical patent/WO2001051051A2/en
Publication of WO2001051051A3 publication Critical patent/WO2001051051A3/en
Priority to US10/192,842 priority patent/US20030032617A1/en
Priority to IL150706A priority patent/IL150706A/en
Publication of WO2001051051B1 publication Critical patent/WO2001051051B1/en
Priority to HK03103749A priority patent/HK1051497A1/en
Priority to US12/242,243 priority patent/US20090098065A1/en
Priority to US15/097,938 priority patent/US20160220589A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention concerns pharmaceutical compositions for the treatment of hyperproliferative diseases of the epidermis such as cancers and psoriasis, as well as for the treatment of aging of the epidermis. The active ingredient can be nicotinamide (NA), cyclic adenosine diphosphate-ribose (cADPR) or a combination of the two.
PCT/IL2001/000017 2000-01-11 2001-01-09 AGENTS, SUCH AS NICOTINAMIDE OR cADPR FOR THE TREATMENT OF SKIN DISORDERS WO2001051051A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
DE60121303T DE60121303T2 (en) 2000-01-11 2001-01-09 MEDIUM, SUCH AS NICOTINAMIDE OR CADPR FOR TREATMENT OF SKIN DISEASES
AU23929/01A AU782558B2 (en) 2000-01-11 2001-01-09 Agents, such as nicotinamide or cADPR for the treatment of skin disorders
EP01900231A EP1259240B8 (en) 2000-01-11 2001-01-09 Agents, such as nicotinamide or cadpr for the treatment of skin disorders
IL15070601A IL150706A0 (en) 2000-01-11 2001-01-09 Composition and methods for the treatment of skin disorders
CA2396186A CA2396186C (en) 2000-01-11 2001-01-09 Agents for the treatment of skin disorders
US10/192,842 US20030032617A1 (en) 2000-01-11 2002-07-11 Composition and methods for the treatment of skin disorders
IL150706A IL150706A (en) 2001-01-09 2002-07-11 Combinations of nicotinamide and vitamin d agents and use thereof in preparation of compositions for the treatment of skin disorders
HK03103749A HK1051497A1 (en) 2000-01-11 2003-05-27 Agents, such as nicotinamide or cadpr for the treatment of skin disorders
US12/242,243 US20090098065A1 (en) 2000-01-11 2008-09-30 Composition and methods for the treatment of skin disorders
US15/097,938 US20160220589A1 (en) 2000-01-11 2016-04-13 Compositions and methods for the treatment of skin disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL133976A IL133976A (en) 2000-01-11 2000-01-11 Agents for the treatment of skin disorders
IL133976 2000-01-11

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/IL2006/000552 Continuation-In-Part WO2006120681A2 (en) 2000-01-11 2006-05-10 Compositions and methods for skin care
US91409308A Continuation-In-Part 2000-01-11 2008-06-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/192,842 Continuation-In-Part US20030032617A1 (en) 2000-01-11 2002-07-11 Composition and methods for the treatment of skin disorders

Publications (3)

Publication Number Publication Date
WO2001051051A2 WO2001051051A2 (en) 2001-07-19
WO2001051051A3 true WO2001051051A3 (en) 2002-06-27
WO2001051051B1 WO2001051051B1 (en) 2002-09-26

Family

ID=11073692

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2001/000017 WO2001051051A2 (en) 2000-01-11 2001-01-09 AGENTS, SUCH AS NICOTINAMIDE OR cADPR FOR THE TREATMENT OF SKIN DISORDERS

Country Status (11)

Country Link
US (1) US20030032617A1 (en)
EP (1) EP1259240B8 (en)
AT (1) ATE332136T1 (en)
AU (1) AU782558B2 (en)
CA (1) CA2396186C (en)
DE (1) DE60121303T2 (en)
DK (1) DK1259240T3 (en)
ES (1) ES2267706T3 (en)
HK (1) HK1051497A1 (en)
IL (2) IL133976A (en)
WO (1) WO2001051051A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090098065A1 (en) * 2000-01-11 2009-04-16 Avikam Harel Composition and methods for the treatment of skin disorders
US7297480B2 (en) * 2001-06-28 2007-11-20 Dermtech International Method for detection of melanoma
US8084049B2 (en) 2002-06-20 2011-12-27 Astion Dermatology A/S Complexes of fatty acid esters of polyhydroxyalkanes and pyridine carboxy derivatives
AU2003242965B2 (en) * 2002-07-11 2009-02-05 Dermipsor Ltd. Composition and methods for the treatment of skin disorders
US7357950B2 (en) 2003-03-21 2008-04-15 Elizabeth Anne Mazzio Topical treatment for dyshidrosis (pompholyx) and dry skin disorders
US7666451B2 (en) 2003-03-21 2010-02-23 Elizabeth Anne Mazzio Method of treating dyshidrosis(pompholyx) and related dry skin disorders
GB0403041D0 (en) * 2004-02-11 2004-03-17 Milner Anne J Induction of apoptosis
US7183057B2 (en) * 2004-03-31 2007-02-27 Dermtech International Tape stripping methods for analysis of skin disease and pathological skin state
DK1879595T3 (en) * 2005-05-10 2015-01-05 Dermipsor Ltd Preparations and Methods for the Treatment of Hyperproliferative Epidermal Diseases
US8034788B2 (en) 2005-05-10 2011-10-11 Dermipsor Ltd. Composition and methods for skin care
US20070183995A1 (en) * 2006-02-09 2007-08-09 Conopco, Inc., D/B/A Unilever Compounds useful as agonists of A2A adenosine receptors, cosmetic compositions with A2A agonists and a method for using the same
GB0619860D0 (en) * 2006-10-06 2006-11-15 Birkeland Innovasjon As Treatment of insulin resistance and disorders associated therewith
US20080173558A1 (en) * 2007-01-22 2008-07-24 Contelanea Arvanitis Fragrance-emanating nasal mask device and method
US20080274908A1 (en) * 2007-05-04 2008-11-06 Dermtech International Diagnosis of melanoma by nucleic acid analysis
JP2011520451A (en) 2008-05-14 2011-07-21 ダームテック インターナショナル Diagnosis of melanoma and Nikko Kuroko by nucleic acid analysis
US20100086501A1 (en) * 2008-08-28 2010-04-08 Dermtech International Determining Age Ranges of Skin Samples
EP3288531B1 (en) * 2015-05-01 2019-07-24 The Procter and Gamble Company Method of improving skin health and compositions therefor
US11013678B2 (en) 2015-06-29 2021-05-25 The Procter & Gamble Company Multi-component skin care product
CN112315837B (en) 2016-01-11 2021-12-03 宝洁公司 Methods of treating skin conditions and compositions therefor
US10660838B2 (en) 2017-06-23 2020-05-26 The Procter & Gamble Company Composition and method for improving the appearance of skin
KR102069088B1 (en) * 2018-04-02 2020-01-22 양미경 Pharmaceutical or cosmetic composition for preventing or treating hair loss or stimulating hair growth
JP2021530447A (en) 2018-07-03 2021-11-11 ザ プロクター アンド ギャンブル カンパニーThe Procter & Gamble Company How to treat skin condition
AU2020247911A1 (en) 2019-03-26 2021-11-11 Dermtech, Inc. Novel gene classifiers and uses thereof in skin cancers
WO2020227625A1 (en) * 2019-05-08 2020-11-12 Laura Hansen 14-3-3 targeting peptides for cancer treatment
US11685766B2 (en) 2019-05-08 2023-06-27 Creighton University 14-3-3 targeting peptides for cancer treatment
US11583488B2 (en) 2020-06-01 2023-02-21 The Procter & Gamble Company Method of improving penetration of a vitamin B3 compound into skin
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0052705A1 (en) * 1980-11-24 1982-06-02 Joel E. Bernstein, M.D. Composition for treating acne vulgaris
HU209067B (en) * 1991-12-30 1994-03-28 Tatar Process for the production of hair-fall moderating preparation
DE4335454A1 (en) * 1993-10-19 1995-04-20 Schleicher Peter Geriatric medical composition
WO1998052529A1 (en) * 1997-05-23 1998-11-26 The Procter & Gamble Company Skin care compositions comprising vitamin b3 and a skin conditioning component
DE29916231U1 (en) * 1999-09-15 2000-02-17 Renner Jobst Multivitamin and mineral preparation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067975A (en) * 1975-08-04 1978-01-10 Yu Ruey J Treatment of psoriasis with 6-aminonicotinamide and thionicotinamide
US6248763B1 (en) * 1998-05-19 2001-06-19 Scivoletto Rosemarie Composition for treating skin conditions
US6429218B1 (en) * 1997-05-19 2002-08-06 Joseph Scivoletto Method of controlling niacin concentration in lotion
US6107349A (en) * 1998-04-16 2000-08-22 Mantynen; Philip R. Method and composition for treating psoriasis

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0052705A1 (en) * 1980-11-24 1982-06-02 Joel E. Bernstein, M.D. Composition for treating acne vulgaris
HU209067B (en) * 1991-12-30 1994-03-28 Tatar Process for the production of hair-fall moderating preparation
DE4335454A1 (en) * 1993-10-19 1995-04-20 Schleicher Peter Geriatric medical composition
WO1998052529A1 (en) * 1997-05-23 1998-11-26 The Procter & Gamble Company Skin care compositions comprising vitamin b3 and a skin conditioning component
DE29916231U1 (en) * 1999-09-15 2000-02-17 Renner Jobst Multivitamin and mineral preparation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Derwent World Patents Index; AN 1994-170436, XP002183599, FORGACS ET AL *
MORIMOTO ET AL: "an open study of vitamin D3 treatment in psoriasis vulgaris", BRITISH JOURNAL OF DERMATOLOGY, vol. 115, 1986, pages 421 - 429, XP000905334 *

Also Published As

Publication number Publication date
CA2396186A1 (en) 2001-07-19
AU782558B2 (en) 2005-08-11
EP1259240B1 (en) 2006-07-05
EP1259240A2 (en) 2002-11-27
IL133976A (en) 2006-09-05
DK1259240T3 (en) 2006-10-30
ATE332136T1 (en) 2006-07-15
DE60121303D1 (en) 2006-08-17
DE60121303T2 (en) 2007-06-14
ES2267706T3 (en) 2007-03-16
WO2001051051B1 (en) 2002-09-26
WO2001051051A2 (en) 2001-07-19
CA2396186C (en) 2011-03-22
IL150706A0 (en) 2003-02-12
HK1051497A1 (en) 2003-08-08
AU2392901A (en) 2001-07-24
US20030032617A1 (en) 2003-02-13
IL133976A0 (en) 2001-04-30
EP1259240B8 (en) 2007-05-09

Similar Documents

Publication Publication Date Title
WO2001051051A3 (en) Agents, such as nicotinamide or cadpr for the treatment of skin disorders
MXPA04004966A (en) 3-beta-D-RIBOFURANOSYLTHIAZOLO[4,5-d.
IL180528A0 (en) Pharmaceutical formulations for treating mitochondrial disorders
WO2002076472A3 (en) Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs
IL154888A (en) Non-aqueous pharmaceutical gel composition containing at least one vitamin d or one vitamin d analogue and at least one corticosteroid and its use in the manufacture of a medicament for treatment of psoriasis
HUP0301167A3 (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders, process for their preparation, pharmaceutical compositions containing them and their use
TNSN06403A1 (en) 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
IL172423A0 (en) Novel formulations for opioid -based treatments of pain comprising substituted 1,4-di-piperidin-4-yl-piperazine derivatives
AU2108500A (en) Galenic formulation containing biotin
WO2002051379A3 (en) Thixotropic nasal spray
PL346767A1 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
HUP0600084A2 (en) Pharmaceutical compositions containing ascorbic acid derivatives, methods of production of the active ingredient
WO2002017893A3 (en) Sgk2 and sgk3 used as diagnostic and therapeutic targets
HK1057332A1 (en) Use of 3-benzoylphenylacetic acid derivatives for the treatment of retinal disorders
WO2000061231A3 (en) Medical use
EP0373771A3 (en) New pharmaceutical uses for cystatins
HK1065305A1 (en) Substituted 4-aminocyclohexanol derivatives
AU2003227593A1 (en) New analogs of nitrobenzylthioinosine
WO2004006887A3 (en) Composition and methods for the treatment of skin disorders
WO2003024996A3 (en) Antibacterial macrocycles
WO2003043632A3 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
HUP0204180A2 (en) External composition and its use for treating of allergic skin diseases
AU2001273801A1 (en) Dehydrobaimuxinol derivatives use as medicaments for treating or preventing regressive diseases of brain
PL355113A1 (en) Novel fusidic acid derivatives
IL159789A0 (en) Active ingredient combination for pharmacological therapy of nicotine dependence

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2396186

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 23929/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 150706

Country of ref document: IL

Ref document number: 10192842

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001900231

Country of ref document: EP

AK Designated states

Kind code of ref document: B1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2001900231

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWG Wipo information: grant in national office

Ref document number: 23929/01

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2001900231

Country of ref document: EP